These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858 [TBL] [Abstract][Full Text] [Related]
14. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318 [TBL] [Abstract][Full Text] [Related]
15. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745 [TBL] [Abstract][Full Text] [Related]
16. Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort. Hirtz C; Busto GU; Bennys K; Kindermans J; Navucet S; Tiers L; Lista S; Vialaret J; Gutierrez LA; Dauvilliers Y; Berr C; Lehmann S; Gabelle A Alzheimers Res Ther; 2023 Feb; 15(1):34. PubMed ID: 36800984 [TBL] [Abstract][Full Text] [Related]
17. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Benedet AL; Brum WS; Hansson O; ; Karikari TK; Zimmer ER; Zetterberg H; Blennow K; Ashton NJ Alzheimers Res Ther; 2022 Feb; 14(1):26. PubMed ID: 35130933 [TBL] [Abstract][Full Text] [Related]
18. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O; Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982 [TBL] [Abstract][Full Text] [Related]
19. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. Hu Y; Kirmess KM; Meyer MR; Rabinovici GD; Gatsonis C; Siegel BA; Whitmer RA; Apgar C; Hanna L; Kanekiyo M; Kaplow J; Koyama A; Verbel D; Holubasch MS; Knapik SS; Connor J; Contois JH; Jackson EN; Harpstrite SE; Bateman RJ; Holtzman DM; Verghese PB; Fogelman I; Braunstein JB; Yarasheski KE; West T JAMA Netw Open; 2022 Apr; 5(4):e228392. PubMed ID: 35446396 [TBL] [Abstract][Full Text] [Related]
20. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline. Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M; Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]